Evotec SE, a drug discovery and development life science company, has signed off on the sale of the Just – Evotec Biologics Toulouse site to Sandoz AG, a global manufacturer of generic and biosimilar medicines.

Under the transaction, Sandoz will acquire Just – Evotec Biologics EU plus an indefinite technology license to Evotec’s continuous manufacturing platform technology for a payment of approximately $350 million in cash. The agreement includes additional license fees and development revenues including milestones totaling more than $300 million. 

Evotec expects to benefit from royalties on a portfolio of up to ten biosimilars in technical and early development targeting a net originator sales market of more than $ 90 billion.

With this acquisition, Sandoz will gain access to Evotec’s platform for integrated development and advanced continuous manufacturing of biologics via an indefinite license.

The companies aim to close the transaction in 4Q25 subject to meeting closing conditions.